We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Test Detects Return of Blood Cancer a Year Earlier

By LabMedica International staff writers
Posted on 19 Jun 2024
Print article
Image: The new test’s measurement is a thousand times more sensitive than current standard test (Photo courtesy of 123RF)
Image: The new test’s measurement is a thousand times more sensitive than current standard test (Photo courtesy of 123RF)

Multiple myeloma, also known as Kahler's disease, is a type of blood cancer originating in the bone marrow characterized by the uncontrolled proliferation of plasma cells, a specific type of white blood cell. Remarkably, half of the patients initially respond to treatment to a degree where the disease becomes undetectable in their blood, but unfortunately, the disease almost invariably returns. Currently, to monitor for the return of the disease, the standard practice involves a bone marrow biopsy, an invasive procedure that is not feasible to perform frequently. This method's reliability can also vary since the disease may not be uniformly distributed across the bone marrow. Alternatively, a less sensitive blood test is available, but it only detects the disease's return when the cancer cell count is considerably elevated. Now, researchers have developed a new blood test that can detect the return of multiple myeloma a full year earlier than the current standard blood test.

This advanced blood test, developed by scientists at Radboud University Medical Center (Nijmegen, the Netherlands) in collaboration with Erasmus MC (Rotterdam, Netherlands), is a thousand times more sensitive than the currently used blood test. It works by measuring antibodies produced by plasma cells, which are crucial to immune defense. Normally, a variety of plasma cells produce antibodies to combat different pathogens, but in multiple myeloma, one plasma cell type multiplies excessively, producing numerous identical plasma cells and antibodies, which the new test targets. Initially, customizing the test for individual patients required 125 days, but researchers have now refined the process to accommodate any patient and simultaneously test 25 patients, reducing the development time to just five days.

Moreover, the team has developed new software that enhances the measurement process, enabling even faster detection of tumor cell signals. In a trial involving forty patients, this test proved capable of detecting increases in cancer cells a year earlier than the standard blood test. The procedure needs less than a drop of blood, making it minimally invasive. Researchers are also exploring the possibility of patients performing the blood collection at home via a simple finger prick, which would bypass the need for hospital visits for blood draws, further innovating patient care in this field.

“Patients whose disease is no longer measurable after treatment often live in uncertainty for years”, said Hans Jacobs, Medical Immunologist. “With the new blood test, you can monitor much better, providing clarity. When the current blood test shows the cancer's return, the number of cancer cells is already high, and a different therapy is initiated. With the new test, we see the increase in cancer cells much earlier. This may allow for quicker and better adaptation of therapy to the patient’s situation, but we don’t know that yet. We will investigate this.”

Related Links:
Radboud University Medical Center 
Erasmus MC 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.